Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
Kyaw Aung(Baptist Health South Florida), Jennifer J. Knox(National Cancer Center), David W. Hedley(Ontario Institute for Cancer Research), Ashton A. Connor(Ontario Institute for Cancer Research), Steven Gallinger(Ontario Institute for Cancer Research), Grainne M. O’Kane(University College Dublin), Neesha C. Dhani(Princess Margaret Cancer Centre), Richard A. Moffitt(Emory University), Danielle Pasternack(Ontario Institute for Cancer Research), Bernadette Southwood(Princess Margaret Cancer Centre), Anna Dodd(Princess Margaret Cancer Centre), Sheng‐Ben Liang(University Health Network), Hamzeh Albaba(Princess Margaret Cancer Centre), Sangeet Ghai(University Health Network), Faridah Mbabaali(Ontario Institute for Cancer Research), Paul M. Krzyzanowski(Ontario Institute for Cancer Research), Mathieu Lemire(Ontario Institute for Cancer Research), Malcolm J. Moore(University Health Network), Amy Zhang(Ontario Institute for Cancer Research), Jessica K. Miller(Ontario Institute for Cancer Research), Faiyaz Notta(Ontario Institute for Cancer Research), Jen Jen Yeh(University of North Carolina at Chapel Hill), Lee E. Timms(Ontario Institute for Cancer Research), Ilinca M. Lungu(Ontario Institute for Cancer Research), Julie M. Wilson(Ontario Institute for Cancer Research), Shari Moura(Princess Margaret Cancer Centre), Sandra E. Fischer(University Health Network), Robert C. Grant(Princess Margaret Cancer Centre), Robert E. Denroche(Ontario Institute for Cancer Research), Sean Creighton(Princess Margaret Cancer Centre), John M.S. Bartlett(Edinburgh Cancer Research), Spring Holter(Lunenfeld-Tanenbaum Research Institute), Gun-Ho Jang(Ontario Institute for Cancer Research), Dianne Chadwick(University Health Network)
Cited by 635
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k